CRISPR/Cas9 technology introduced a C to T change at chr16:20,712,754 (GRCm38) resulting in an arginine to glutamine substitution at amino acid 180 (R180Q) in exon 5. The mouse R180Q is homologous to human R172Q that is commonly mutated in familial hyperaldosteronism type II.